Advaxis names VP, clinical ops
This article was originally published in Scrip
Executive Summary
Advaxis, a clinical-stage biotechnology company developing cancer immunotherapies, has appointed Thomas W Hare vice-president of clinical operations. Mr Hare brings to Advaxis more than 28 years of experience in the biopharmaceutical and contract research organization industries overseeing the management of global commercial and clinical operations, data management, outsourcing and medical writing groups. Most recently, he was vice-president of drug development operations at Incyte. In his new role he will report to Advaxis' executive vice-president, chief medical officer, Dr David J Mauro, and will oversee clinical operations for the company's multiple Lm-LLO cancer immunotherapy clinical programs.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.